Oruka Therapeutics (NASDAQ:ORKA) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report published on Monday,Benzinga reports. They currently have a $45.00 price target on the stock. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($2.24) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

A number of other research analysts have also recently issued reports on ORKA. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Leerink Partners began coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price for the company. Wedbush restated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Finally, TD Cowen initiated coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $20.26 on Monday. Oruka Therapeutics has a 12 month low of $18.20 and a 12 month high of $53.88. The stock has a market capitalization of $709.08 million, a price-to-earnings ratio of -3.24 and a beta of 0.87. The firm’s fifty day moving average price is $25.67.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at $343,000. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics during the 3rd quarter valued at about $1,037,000. Wellington Management Group LLP bought a new stake in shares of Oruka Therapeutics in the third quarter worth approximately $2,013,000. Janus Henderson Group PLC purchased a new position in shares of Oruka Therapeutics during the third quarter valued at approximately $5,840,000. Finally, Redmile Group LLC bought a new position in Oruka Therapeutics during the third quarter valued at approximately $10,091,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.